New Study Helps Explain Why Severe Virus Attacks on the Lungs

New study describes how macrophages develop in the lungs and which of them may be behind severe lung diseases.

A new study conducted by Karolinska Institutet researchers describes how different kinds of immune cells, called macrophages, develop in the lungs and which of them may be behind severe lung diseases. The findings of the study are published in Immunity.

The structure of the lungs exposes them to viruses and bacteria from both the air and the blood. Macrophages are immune cells that, among other things, protect the lungs from such attacks.

Respiratory Diseases - Diseases of the Human Respiratory System
Respiratory diseases affect any part of the respiratory system. Some of the lung diseases like chronic obstructive pulmonary disease can lead to respiratory failure.

‘In infection with the novel coronavirus, SARS-COV-2, which causes COVID-19, researchers believe that pro-inflammatory lung macrophages from blood monocytes replace protective, anti-inflammatory macrophages.’

But under certain conditions, lung macrophages can also contribute to severe lung diseases, such as chronic obstructive pulmonary disease (COPD) and COVID-19.

To date, research on the development of human lung macrophages has been limited.

Macrophages can have different origins and develop, among other things, from white blood cells, monocytes, that are divided into different genetically determined main types. In humans, two of these are "classical" CD14+ monocytes and "non-classical" CD16+ monocytes.

The Lungs
The lungs are our organs of respiration. It is within these, that exchange of gases takes place.

In a new study at Karolinska Institutet, researchers have used a model to study the development of lung macrophages directly in a living lung. This has been combined with a method to study gene activity in individual cells, RNA sequencing, and thereby discovered how blood monocytes become human lung macrophages.

"In our study, we show that classical monocytes migrate into airways and lung tissue and are converted into macrophages that protect the health and function of the lungs. We have also identified a special kind of monocyte, HLA-DRhi, which is an intermediate immune cell between a blood monocyte and an airway macrophage. These HLA-DRhi monocytes can leave the blood circulation and migrate into the lung tissue," says Tim Willinger, Associate Professor at the Department of Medicine, Huddinge, Karolinska Institutet, who led the study.

Nintedanib Slows Progression of Scarring Lung Diseases: Study
New study findings suggest all progressive, scarring lung diseases may share similar mechanisms and many more people may benefit from Nintedanib more than currently approved treatment.

The non-classical monocytes, however, develop into macrophages in the many blood vessels of the lungs and do not migrate into the lung tissue.

"Certain macrophages in the lungs probably have a connection to a number of severe lung diseases. In respiratory infections, for example, monocytes in the lungs develop into macrophages, which combat viruses and bacteria.

Occupational Hazards Linked to Non-cancerous Lung Diseases
Occupational hazards were found to account for more than one in ten people with range of non-cancerous lung diseases, said new study.

But a certain type of macrophage may also contribute to severe inflammation and infections," says the study's first author Elza Evren, a doctoral student in Tim Willinger's research team.

"The existence of these blood monocyte-derived macrophages has been shown in other studies to correlate with how severely ill a person becomes in COVID-19 and how extensive the damage to the lungs is. Patients with severe COVID-19 also have fewer HLA-DRhi monocytes in their blood, probably because they move away from the blood into the lungs. Given their important role in rapid inflammatory responses, our results indicate that future treatments should focus on inflammatory macrophages and monocytes to reduce lung damage and mortality from severe COVID-19," says Tim Willinger.

Source-Eurekalert